GlaxoSmithKline Historical Income Statement
| GSK Stock | USD 33.70 0.35 1.05% |
Historical analysis of GlaxoSmithKline PLC income statement accounts such as Total Revenue of 19.9 B or Gross Profit of 14.6 B can show how well GlaxoSmithKline PLC ADR performed in making a profits. Evaluating GlaxoSmithKline PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of GlaxoSmithKline PLC's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining GlaxoSmithKline PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GlaxoSmithKline PLC ADR is a good buy for the upcoming year.
GlaxoSmithKline |
About GlaxoSmithKline Income Statement Analysis
GlaxoSmithKline PLC ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to GlaxoSmithKline PLC shareholders. The income statement also shows GlaxoSmithKline investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
GlaxoSmithKline PLC Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts GlaxoSmithKline PLC ADR generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of GlaxoSmithKline PLC ADR minus its cost of goods sold. It is profit before GlaxoSmithKline PLC operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of GlaxoSmithKline PLC ADR. It is also known as GlaxoSmithKline PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from GlaxoSmithKline PLC ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of GlaxoSmithKline PLC ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on GlaxoSmithKline PLC income statement and is an important metric when analyzing GlaxoSmithKline PLC ADR profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from GlaxoSmithKline PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At this time, GlaxoSmithKline PLC's Net Income From Continuing Ops is quite stable compared to the past year. Discontinued Operations is expected to rise to about 12.7 B this year, although the value of Gross Profit will most likely fall to about 14.6 B.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 784M | 879M | 775M | 502.2M | Depreciation And Amortization | 2.1B | 2.1B | 2.3B | 2.4B |
GlaxoSmithKline PLC income statement Correlations
Click cells to compare fundamentals
GlaxoSmithKline PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GlaxoSmithKline PLC income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 171.9K | 2.4B | 2.1B | 2.1B | 2.3B | 2.4B | |
| Interest Expense | 912M | 892M | 784M | 879M | 775M | 502.2M | |
| Total Revenue | 33.8B | 34.1B | 34.1B | 29.3B | 30.3B | 19.9B | |
| Gross Profit | 21.9B | 22.4B | 22.5B | 19.8B | 21.3B | 14.6B | |
| Other Operating Expenses | 26.8B | 26.3B | 27.9B | 22.9B | 23.6B | 15.3B | |
| Operating Income | 7.0B | 6.0B | 4.4B | 6.4B | 6.7B | 4.9B | |
| Ebit | 10.1B | 5.7B | 5.6B | 6.5B | 6.8B | 5.4B | |
| Research Development | 4.6B | 5.1B | 5.3B | 5.5B | 6.2B | 6.5B | |
| Ebitda | 10.1B | 8.1B | 7.8B | 8.6B | 9.1B | 6.4B | |
| Total Operating Expenses | 14.9B | 14.6B | 16.3B | 13.3B | 15.0B | 10.0B | |
| Income Before Tax | 6.2B | 5.2B | 3.6B | 5.6B | 6.1B | 4.7B | |
| Total Other Income Expense Net | (740M) | (809M) | (758M) | (805M) | (681M) | (647.0M) | |
| Net Income | 4.6B | 5.7B | 4.4B | 15.0B | 4.9B | 3.7B | |
| Income Tax Expense | 953M | 67M | 83M | 707M | 756M | 1.2B | |
| Selling General Administrative | 11.4B | 11.5B | 11.0B | 8.4B | 9.4B | 9.8B | |
| Cost Of Revenue | 11.9B | 11.7B | 11.6B | 9.6B | 9.1B | 7.7B | |
| Net Income Applicable To Common Shares | 4.6B | 5.7B | 4.4B | 15.0B | 13.5B | 14.1B | |
| Minority Interest | 7.0B | 6.2B | (711M) | (665M) | (380M) | (361M) | |
| Net Income From Continuing Ops | 5.3B | 6.4B | 5.1B | 4.9B | 6.5B | 9.4B | |
| Tax Provision | 953M | 580M | 346M | 707M | 756M | 669.3M | |
| Interest Income | 708M | 44M | 723M | 76M | 48M | 45.6M | |
| Net Interest Income | (840M) | (848M) | (756M) | (803M) | (735M) | (771.8M) | |
| Reconciled Depreciation | 2.3B | 2.4B | 2.5B | 2.3B | 1.5B | 1.7B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.54 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.